Oncology Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      Haematology

      Click one of the buttons below to find out more:

      Prescribing Information can be found below.
      Acute Myeloid Leukaemia (AML)
      Chronic Lymphocytic Leukaemia (CLL)
      Diffuse Large B-Cell Lymphoma (DLBCL)
      VENCLYXTO AML PRESCRIBING INFORMATION
      VENCLYXTO CLL PRESCRIBING INFORMATION
      TEPKINLY PRESCRIBING INFORMATION

      By clicking the links above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

       

      Tepkinly has a conditional marketing authorisation - further data awaited.

      UK-ONC-240050. Date of Preparation: November 2024.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.